Prothena Corporation

Prothena Corporation EBIT

The EBIT of Prothena Corporation (PRTA) as of Oct 3, 2026 is -184.56 M USD. In the previous year, EBIT was -154.56 M USD — a change of 19.41% (lower).

EBIT

-184.56 MUSD

YoY

19.41%

Last updated:

In 2026, Prothena Corporation's EBIT was -184.56 M USD, a 19.41% increase from the -154.56 M USD EBIT recorded in the previous year.

The Prothena Corporation EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-191.04 M USD
Jan 1, 2024
-154.56 M USD
Jan 1, 2025
-184.56 M USD
Jan 1, 2026 (e)
1.40 M USD
Jan 1, 2027 (e)
-45.33 M USD
Jan 1, 2028 (e)
-16.19 M USD
Jan 1, 2029 (e)
-9.42 M USD
Jan 1, 2030 (e)
126.26 M USD
The Prothena Corporation EBIT history
YEAREBITYoY
est126.26 MUSD-1,440.28%
est-9.42 MUSD-41.81%
est-16.19 MUSD-64.28%
est-45.33 MUSD-3,346.53%
est1.40 MUSD-100.76%
-184.56 MUSD+19.41%
-154.56 MUSD-19.09%
-191.04 MUSD+45.21%
-131.56 MUSD-282.78%
71.98 MUSD-163.84%
-112.73 MUSD+31.55%
-85.70 MUSD-46.05%
-158.86 MUSD+0.89%
-157.46 MUSD-1.30%
-159.54 MUSD+99.58%
-79.94 MUSD+1,102.24%
-6.65 MUSD-83.55%
-40.43 MUSD-2.37%
-41.41 MUSD+41.60%
-29.24 MUSD+140.45%
-12.16 MUSD+913.50%
-1.20 MUSD—
Access this data via the Eulerpool API

Prothena Corporation Revenue

Prothena Corporation Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
91.37 M USD
-191.04 M USD
-147.03 M USD
Jan 1, 2024
135.16 M USD
-154.56 M USD
-122.31 M USD
Jan 1, 2025
9.68 M USD
-184.56 M USD
-244.09 M USD
Jan 1, 2026 (e)
83.16 M USD
1.40 M USD
5.92 M USD
Jan 1, 2027 (e)
29.25 M USD
-45.33 M USD
-49.97 M USD
Jan 1, 2028 (e)
134.77 M USD
-16.19 M USD
7.27 M USD
Jan 1, 2029 (e)
200.54 M USD
-9.42 M USD
-9.42 M USD
Jan 1, 2030 (e)
265.60 M USD
126.26 M USD
119.37 M USD

Prothena Corporation Margins

Prothena Corporation stock margins

The Prothena Corporation margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Prothena Corporation. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Prothena Corporation.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
100.00 %
-209.08 %
-160.91 %
Jan 1, 2024
100.00 %
-114.36 %
-90.49 %
Jan 1, 2025
61.77 %
-1,905.82 %
-2,520.57 %
Jan 1, 2026 (e)
61.77 %
1.68 %
7.12 %
Jan 1, 2027 (e)
61.77 %
-154.97 %
-170.84 %
Jan 1, 2028 (e)
61.77 %
-12.01 %
5.39 %
Jan 1, 2029 (e)
61.77 %
-4.70 %
-4.70 %
Jan 1, 2030 (e)
61.77 %
47.54 %
44.94 %

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Prothena Corporation's EBIT

Prothena Corporation's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Prothena Corporation's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Prothena Corporation's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Prothena Corporation’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Prothena Corporation stock

EBIT of Prothena Corporation is -184.56 M USD in 2026.

EBIT of Prothena Corporation changed from -154.56 M USD to -184.56 M USD, representing a 19.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Prothena Corporation historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Prothena Corporation

All Key Metrics — Prothena Corporation